ArticleBMC plant biology2026
Jidongwangia sp. JTT04 as a novel bioinoculant: promoting growth and modulating the metabolic profile of Ashwagandha (Withania somnifera (L.) Dunal).
Article in BMC plant biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the medicinal importance of Withania somnifera (L.) Dunal (Ashwagandha), a significant knowledge gap remains regarding how endophytic microbes mechanistically reprogram host metabolism to enhance both growth and biological value. This study addresses this gap by exploring the biofortification capacity of Jidongwangia sp. JTT04, a newly isolated endophytic actinobacterium from Tribulus terrestris, in enhancing the growth, biochemical profile, and functional properties of Ashwagandha. Inoculation with JTT04 significantly improved shoot biomass and enhanced carbon assimilation provides the essential precursors for primary metabolism, driving a significant surge in glucose, fructose, and starch. These carbohydrates serve as the carbon skeleton for the accelerated synthesis of organic acids (citric and succinic) and amino acids, alongside an enriched pool of saturated and unsaturated fatty acids. This robust primary metabolic foundation subsequently fuels the shikimate and phenylpropanoid pathways, triggering the overproduction of high-value secondary metabolites, including phenolic acids (caffeic, rosmarinic) and flavonoids (rutin, kaempferol). Consequently, this integrated metabolic redirection directly translates into superior biochemical and functional values, evidenced by a 1.51-fold increase in antioxidant capacity (FRAP), potent anti-inflammatory effects (Cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibition), and broad-spectrum antibacterial activity. By mechanistically linking nutrient assimilation to biological value, JTT04 offers a transformative strategy for the sustainable biofortification of Ashwagandha.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.